Kay Azzara, RPAC

Kay Azzara practices at Dr Donna a Serure, Dermatology & Cosmetic Laser Surgery in Smithtown, New York.

Kay Azzara's NPI, 1255574026, was assigned on April 9, 2009. Kay Azzara holds New York license 013088-1.

Kay Azzara's primary practice is Dr Donna a Serure, Dermatology & Cosmetic Laser Surgery, at 327 E Main St, Smithtown, NY 11787 in Suffolk County. The practice phone is (631) 979-0909.

Kay Azzara's primary practice is Dr Donna a Serure, Dermatology & Cosmetic Laser Surgery in Smithtown, New York. The medical group on file is Rockville Dermatology. Dmand AI also links Kay Azzara to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Kay Azzara practices, 2 sites in all. Vendor and product names are available with a free account.

Physician assistant is Kay Azzara's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Kay Azzara is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Kay Azzara is licensed in New York.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cold sores or genital herpes, contact dermatitis, itchy rashes, joint cyst and minor injury on trunk among the conditions Kay Azzara treats.

CMS data shows 4,527 Medicare services from Kay Azzara across 12 procedure codes in 2024, for 1,055 Medicare patients. Medicare paid $201,320 for them. Every service was in an office.

CMS counts 1,055 Medicare patients who saw Kay Azzara in 2024. The largest group is 65 to 74, with 479 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.10, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Kay Azzara's median patient age at 54, with 60% women.

In 2024, Kay Azzara wrote 979 Medicare Part D claims for 577 patients. 85% of them were for generic drugs. CMS names the drug for 867 of them, across 17 drugs with 11 or more claims each, at $53,568 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 65 out of 100 for Kay Azzara for performance year 2024, reported individually. Kay Azzara accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 39 general payments to Kay Azzara from 15 drug and device companies in 2025. Food and beverage make up the largest share, 100% of the total. Arcutis Biotherapeutics, Inc. paid the most, $265.